Preclinical pharmacology of neuroleptics: Focus on new generation compounds

Elliott Richelson

Research output: Contribution to journalReview articlepeer-review

155 Scopus citations

Abstract

This article reviews the preclinical pharmacology of neuroleptics, with focus on the newer generation compounds: clozapine, risperidone, olanzapine, sertindole, and quetiapine. All of these newer compounds are considered to be atypical neuroleptics, based on certain criteria, which are reviewed. Several hypotheses about the molecular mechanisms that explain atypicality are considered. Finally, the in vitro receptor binding data presented for these and some older compounds are related to the therapeutic and adverse effects of these drugs.

Original languageEnglish (US)
Pages (from-to)4-11+46
JournalJournal of Clinical Psychiatry
Volume57
Issue numberSUPPL. 11
StatePublished - 1996

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Preclinical pharmacology of neuroleptics: Focus on new generation compounds'. Together they form a unique fingerprint.

Cite this